3to10: Innovation Cancer Models and Translational Programs
Only 3.4% of cancer drugs that start clinical trials make it to market. The lost commercial opportunity is one thing, but the cost to cancer patients is huge. New cancer therapies are simply not reaching the people who need them most. And drugs that should fail earlier are making it to clinic, wasting precious time and money.
3to10 is a series of events with one simple goal: to push clinical success rates for cancer drugs from 3% to 10%.
This is the first of those events: Innovation Cancer Models and Translational Programs.
Location: Cambridge, MA
Date: 26-27 June